CD274 and gastric cancer: As for other PD-L1 inhibitors, for example, a phase Ib/II study in patients with advanced GC/GEJC is currently underway to test the role of durvalumab and tremelimumab as a second- or third-line single-agent and combination therapy (NCT02340975) (35).